Akero Therapeutics Inc
3.37 %
111.77 %
Yet to be announced
Company Overview
Akero Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformational treatments for patients with serious metabolic diseases. The company's lead product candidate is efruxifermin (EFX), which is being developed for the treatment of nonalcoholic steatohepatitis (NASH), a serious liver disease.
The company is currently in pre-revenue phase, focusing on research and development of its drug candidates through clinical trials. Akero operates primarily in the United States and is headquartered in South San Francisco, California.
Revenue Sources
PassAs Akero Therapeutics is a pre-revenue biotech company still in clinical development phase with zero revenue over the past four quarters, this criterion is not applicable at this stage. The company's business model focuses on developing treatments for metabolic diseases, which is a halal business activity.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Since Akero Therapeutics is in pre-revenue phase and still conducting clinical trials, the interest expense ratio check is not applicable at this stage. The company's current expenses are primarily related to research and development activities, which is normal for a clinical-stage biotech company.
Operational Ethics
PassBased on available information from SEC filings and company documents, there is no evidence of any significant ongoing associations with entities involved in human rights violations, including the state of Israel or the Chinese Communist Party.
Comments